Immunotherapy Program at Northside

Northside Hospital’s Immunotherapy Program is a nationally recognized treatment center.

Northside Hospital’s Immunotherapy and CAR T-cell Program FACTS:

  • Within five to ten business days of the initial referral, the relapsed or refractory non-Hodgins’s lymphoma patient, acute lymphocytic leukemia, or multiple myeloma patient will be evaluated by the Northside Hospital’s immunotherapy and CAR T-cell physicians.

  • Dedicated cellular therapy clinical coordinators will organize and coordinate care from new patient consultation through treatment follow-up.

  • With onsite apheresis capabilities at Atlanta Blood Services, our team is able to schedule T-cell apheresis within days of a new patient's consultation.

  • Dedicated financial team that is able to expeditiously obtain financial approval for all immunotherapy treatments, including CAR T-cell.

  • Continuous communication with referring hematologists and oncologists to ensure bridging therapy is initiated if necessary.

  • Please visit immunotherapy clinical trials for a listing of leukemia, multiple myeloma, diffuse large B-cell lymphoma, and other various disease-specific immunotherapy trials.

Available Commercial CAR T-cell Products:

B-CELL MALIGNANCIES

BREYANZI®

Relapsed/Refractory (R/R) Large B-Cell Lymphoma, including:

·       Diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from indolent lymphoma

·       High-grade B-cell lymphoma

·       Primary mediastinal large B-cell lymphoma

·       Follicular lymphoma grade 3B

» Adult patients (18+ years)

» Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line

      chemoimmunotherapy-OR-

» Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age-OR-

» After two (2) or more lines of systemic therapy

TECARTUS®

Relapsed/Refractory (R/R) Mantle Cell Lymphoma

Adult patients (18+ years)

After first line therapy

YESCARTA®

Relapsed/Refractory Large B-cell lymphoma

 » Adult patients (18+ years)

 » Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line

    chemoimmunotherapy

Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma including:

·       Diffuse large B-cell lymphoma not otherwise specified

·       DLBCL arising from follicular lymphoma

·       High-grade B-cell lymphoma

·       Primary mediastinal large B-cell lymphoma

» Adult patients (18+ years)

» After two (2) or more lines of systemic therapy

KYMRIAH®

Relapsed/Refractory (R/R) Large B-Cell Lymphoma, including:

·       Diffuse large B-cell lymphoma not otherwise specified

·       DLBCL arising from follicular lymphoma

·       High-grade B-cell lymphoma

·       Follicular lymphoma

 » Adult patients (18+ years)

 » After two (2) or more lines of systemic therapy

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

TECARTUS®

Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

  » Adult Patients (18+ Years)

KYMRIAH®

B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

  » Patients ≤ 25 years

  » ALL is refractory or in a second or later relapse

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL):

TECARTUS®

Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Adult Patients (18+ Years)

KYMRIAH®

B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Patients ≤ 25 years

ALL is refractory or in a second or later relapse.

MULTIPLE MYELOMA

ABECMA®

Relapsed/Refractory (R/R) Multiple Myeloma*

After four (4) or more prior lines of therapy, including:

» an immunomodulatory agent

» a proteasome inhibitor

» an anti-CD-38 monoclonal antibody

CARVYKTI[KM1] ®

After four (4) or more prior lines of therapy, including:

» an immunomodulatory agent

» a proteasome inhibitor

» an anti-CD-38 monoclonal antibody